Physician profile
Rivkah Horowitz
NPI 1639303084
$6,691.30
in general payments reported to CMS, 2019-2025
55 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $983 · 2022: $1,534 · 2023: $1,212 · 2024: $1,623 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,174.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.52 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $413.50 | 2021-2025 | |
| Lilly USA, LLC | $396.16 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $359.67 | 2021-2025 | |
| Amgen INC. | $329.15 | 2021-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $301.85 | 2021-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $292.53 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.53 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $237.93 | 2021-2025 | Tymlos |
| Genzyme Corporation | $218.32 | 2024-2025 | |
| Corcept Therapeutics | $186.50 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $179.93 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals Lp | $155.15 | 2021-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $154.15 | 2023-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $141.93 | 2021-2025 | Unithroid |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $141.52 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $135.79 | 2022-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $128.27 | 2023-2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $123.99 | 2022-2025 | |
| Pharming Healthcare, INC. | $113.40 | 2024 | Joenja |
| Aimmune Therapeutics, INC. | $107.08 | 2024 | |
| Cequr Corporation | $106.58 | 2023-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $102.54 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Genentech USA, INC. | $100.80 | 2022 | |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Mannkind Corporation | $90.20 | 2021-2023 | Afrezza |
| Almatica Pharma LLC | $67.68 | 2024-2025 | Teriparatide |
| Horizon Therapeutics Plc | $67.05 | 2021-2023 | Tepezza |
| Lifescan, INC. | $65.35 | 2021-2022 | |
| Medtronic, INC. | $63.01 | 2022-2024 | Minimed 780g |
| Antares Pharma, INC. | $61.61 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $61.58 | 2021 | |
| Insulet Corporation | $58.02 | 2022-2025 | Omnipod |
| Dexcom, INC. | $57.78 | 2021-2023 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $50.39 | 2024 | Qutenza |
| Becton, Dickinson and Company | $48.94 | 2021-2022 | |
| Ibsa Pharma INC. | $44.02 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $42.40 | 2024-2025 | |
| Eusa Pharma (US) LLC | $40.99 | 2022 | |
| Embecta Corp. | $40.53 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.45 | 2021 | |
| Pfizer INC. | $23.26 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.56 | 2023 | |
| Soleno Therapeutics, INC. | $21.89 | 2025 | Vykat Xr |
| Zealand Pharma US, INC. | $21.16 | 2021 | |
| Nevro Corp. | $20.14 | 2024 | Senza |
| Kyowa Kirin, INC. | $19.82 | 2023 | |
| Globus Medical, INC. | $18.57 | 2025 | Senza |
| Alfasigma USA, INC. | $17.22 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.96 | 2024 | NP Thyroid 60 |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2024 | Evkeeza |
| Azurity Pharmaceuticals, INC. | $14.64 | 2023 | Adthyza |
| Tolmar, INC. | $13.83 | 2023 | |
| Halozyme INC | $13.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rivkah Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.